Bladder Cancer

Bladder cancer is a form of cancer that insults the bladder. Painless hematuria is one of the most common symptoms but atypical pelvic pain may also occur. It is one of the most common types of cancer and tobacco smoking is one of the most important risk factors. Usually it arises from the urothelial cells that line the inside of the bladder.

CHAPEL HILL- An analysis of evidence from multiple scientific studies found six substances that have a strong link to bladder cancer in the urine of people who had used electronic cigarettes and sometimes other tobacco products, researchers from the University of North Carolina Lineberger Comprehens...

Recently the idea of using chemotherapy has come to seem almost old-fashioned to many patients, who have read about newer and seemingly miraculous "Immunotherapies" - novel drugs that stimulate the immune system to fight cancer. Immunotherapies have dramatically extended the survival of so...

In January 2020, the FDA approved pembrolizumab for the treatment of patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. With muscle-invasive tumors, ph...

In an interview with Targeted Oncology, Massimo Lazzari, MD, Humanitas Clinical Research Hospital, discussed the findings from the analysis of microbiota in patients with bladder cancer. The rationale to investigate the microbiota was to correlate the microbiota with not only bladder cancer but also...

Summary The financial burden of diagnosed bladder cancer is expected to grow between 2018 and 2028 in the seven major markets due to an increase in disease incident cases from over 225,000 to 275,000, at an annual growth rate of 2.New York, March 19, 2020 - Reportlinker.com announces the release of...

One of the more exciting presentations was on the phase Ib/II EV-103 trial, which examined the addition of enfortumab vedotin-ejfv to pembrolizumab in previously untreated patients with locally advanced or metastatic urothelial cancer who were ineligible for cisplatin-based chemotherapy, says Petryl...

In the trial, 157 patients with high-grade, Bacillus Calmette-Guérin-unresponsive nonmuscle-invasive bladder cancer were treated intravesically with the experimental therapy nadofaragene firadenovec. In the following interview, Colin P.N. Dinney, MD, chairman of the department of urology at the Univ...

Altered growth factors and signaling pathways have been found to be drivers of specific types of bladder cancer, said Sumanta Kumar Pal, MD, asso­ciate clinical professor in the Department of Medical Oncology and Therapeutics Research and codirec­tor of the kidney cancer program at City of Hope in D...

The phase Ib/II EV-103 trial examined the use of the antibody-drug conjugate enfortumab vedotin-ejfv in combination with pembrolizumab in previously untreated patients with locally advanced or metastatic urothelial cancer who were ineligible for cisplatin-based chemotherapy. Sonpavde was also involv...

The Bladder Cancer market is expected to significantly grow from $733m in 2018 to $4.0bn by 2028 across the seven major markets at a compound annual growth rate of 18.5%. The exponential growth of the bladder cancer market will be driven by an increasing incident patient population and the approval...

Submit Post

By posting to this website and replying to posts you agree to these rules.